Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

British Journal of Cancer

Volumn 108, Issue 6, 2013, Pages 1306-1315

  Tijono, S M ^a   Guo, K ^a   Henare, K ^a   Palmer, B D ^a   Wang, L C S ^b   Albelda, S M ^b   Ching, L M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 6; INTERLEUKIN 8; UNCLASSIFIED DRUG; VADIMEZAN; XANTHENONE 4 ACETIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STIMULATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LEUKOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN; DRUG COMBINATIONS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LAMININ; LEUKOCYTES; MICE; MICE, NUDE; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEOGLYCANS; XANTHENES; XANTHONES;

EID: 84876412194     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.101     Document Type: Article

References (44)

1. Baguley BC, Ching L-M (2002) DMXAA: an antivascular agent with multiple host responses. Int J Radiation Oncol Biol Phys 54(5): 1503-1511.
2. Bibby M, Phillips R, Double J, Pratesi G (1991) Anti-tumour activity of flavone acetic acid (NSC 347512) in mice-influence of immune status. Br J Cancer 63(1): 57.
3. Brauer R, Wang LCS, Woon ST, Bridewell DJA, Henare K, Malinger D, Palmer BD, Vogel SN, Kieda C, Tijono SM (2010) Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action. Neoplasia (New York, NY) 12(9): 755.
4. Braun RD, Vistisen KS (2012) Modelling human choroidal melanoma xenograft growth in immunocompromised rodents to assess treatment efficacy. Invest Opthal Visual Sci 53(60): 2693-2701.
5. Cao Z, Joseph W, Browne W, Mountjoy K, Palmer B, Baguley B, Ching L (1999) Thalidomide increases both intra-tumoural tumour necrosis factor-a production and anti-tumour activity in response to 5, 6-dimethylxanthenone-4- acetic acid. Br J Cancer 80(5/6): 716.
6. Cheng G, Sun J, Fridlender ZG, Wang LCS, Ching LM, Albelda SM (2010) Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 50 6-dimethylxanthenone-4-acetic acid (Vadimezan). J Biol Chem 285(14): 10553.
7. Ching L, Cao Z, Kieda C, Zwain S, Jameson M, Baguley B (2002) Induction of endothelial cell apoptosis by the antivascular agent 5, 6-dimethylxanthenone- 4-acetic acid. Br J Cancer 86(12): 1937-1942.
8. Ching L, Joseph W, Baguley B (1992) Antitumour responses to flavone-8-acetic acid and 5, 6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 66(1): 128.
9. Ching LM, Goldsmith D, Joseph WR, Körner H, Sedgwick JD, Baguley BC (1999) Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59(14): 3304.
10. Ching LM, Joseph WR, Zhuang L, Atwell GJ, Rewcastle GW, Denny WA, Baguley BC (1991) Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with antitumour activity. Eur J Cancer 27(1): 79-83.
11. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C (2011) IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 71(15): 5296.
12. Henare K, Wang L, Wang LC, Thomsen L, Tijono SM, Chen CJ, Winkler S, Dunbar PR, Print CG, Ching LM (2012) Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA. Br J Cancer 10: 1134-1147.
13. Huang S, Robinson JB, DeGuzman A, Bucana CD, Fidler IJ (2000) Blockade of nuclear factor-kB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60(19): 5334.
14. Jaiswal S, Pazoles P, Woda M, Schultz LD, Greiner DL, Brehm MA, Mathew A (2012) Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology 136: 334-343.
15. Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR (2005) Activation of tumor-associated macrophages by the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid induces an effective CD8\+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 65(24): 11752-11761.
16. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching L-M (1999) Stimulation of tumors to synthesize tumor necrosis factor-a in situ using 5,6-dimethylxanthenone-4-acetic acid. Cancer Res 59(3): 633-638.
17. Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW (2001) Vascular attack by 5, 6-dimethylxanthenone-4-acetic acid combined with B7. 1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res 61(5): 1948-1956.
18. Kline M, Donovan K, Wellik L, Lust C, Jin W, Moon-Tasson L, Xiong Y, Witzig TE, Kumar S, Rajkumar SV (2007) Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leukemia Res 31(5): 591-598.
19. Lara PN, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29(22): 2965.
20. Lash C, Li A, Rutland M, Baguley B, Zwi L, Wilson W (1998) Enhancement of the anti-tumour effects of the antivascular agent 5, 6-dimethylxanthenone-4- acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78(4): 439.
21. Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JPY (2000) IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 164(5): 2769.
22. McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J (2009) Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65(2): 192-197.
23. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA, Wege AJ, Haase AT, Garcia JV (2006) Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 12(11): 1316-1322.
24. Palmer BD, Henare K, Woon ST, Sutherland R, Reddy C, Wang LCS, Kieda C, Ching LM (2007) Synthesis and biological activity of azido analogues of 5, 6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling. J Med Chem 50(16): 3757-3764.
25. Pang JH, Cao Z, Joseph W, Baguley B, Ching LM (1998) Antitumour activity of the novel immune modulator 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. Eur J Cancer 34(8): 1282-1289.
26. Perera PY, Barber SA, Ching LM, Vogel SN (1994) Activation of LPS-inducible genes by the antitumor agent 5, 6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. J Immunol 153(10): 4684-4697.
27. Philpott M, Baguley BC, Ching LM(1995) Induction of tumour necrosis factor-a by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36: 143-148.
28. Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA, Vogel SN (2012) 5,6-Dimethyxanthenone-4-acetic acid (DMXAA) activates Stimulator of Interferon Gene (STING)-dependent inate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem 287(47): 39776-39788.
29. Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34(1): 217-222.
30. Roberts ZJ, Ching LM, Vogel SN (2008) IFN-b-dependent inhibition of tumor growth by the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid (DMXAA). J Interferon Cytokine Res 28(3): 133-139.
31. Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T, Akira S, Savan R, Van Echo D, Fitzgerald KA (2007) The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 204(7): 1559.
32. Strowig T, Gurer C, Ploss A, Lui Y-F, Arrey F, Sashihara J, Koo G, Rice CM, Young JW, Chadburn A, Cohen JI, Munz C (2009) Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 205(6): 1423-1434.
33. Sun J, Wang LCS, Fridlender ZG, Kapoor V, Cheng G, Ching LM, Albelda SM (2011) Activation of mitogen-activated protein kinases by 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation. Biochem Pharmacol 82: 1175-1185.
34. Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC (1991) Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51(1): 77-81.
35. Veszelovszky E, Thomsen LL, Zhuang L, Baguley BC (1993) Flavone acetic acid and 5, 6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis. Eur J Cancer 29(3): 404-408.
36. Wallace A, LaRosa DF, Kapoor V, Sun J, Cheng G, Jassar A, Blouin A, Ching LM, Albelda SM (2007) The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res 67(14): 7011.
37. Wang LCS, Thomsen L, Sutherland R, Reddy CB, Tijono SM, Chen CJJ, Angel CE, Dunbar PR, Ching LM (2009) Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Neoplasia (New York, NY) 11(8): 793.
38. Wang LCS, Woon ST, Baguley BC, Ching LM (2006) Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kB inhibitors. Oncology Res 16(1): 1-14.
39. Waugh DJJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14(21): 6735-6741.
40. Woon ST, Hung SSC, Wu DCF, Schooltink MA, Sutherland R, Baguley BC, Chen Q, Chamley LW, Ching LM (2007) NF-kB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. Anticancer Res 27(1A): 327.
41. Woon ST, Reddy CB, Drummond CJ, Schooltink MA, Baguley BC, Kieda C, Ching LM (2005) A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kB in murine and human cell lines. Oncology Res 15(8): 351-364.
42. Woon ST, Zwain S, Schooltink M, Newth A, Baguley B, Ching LM (2003) NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid (DMXAA). Eur J Cancer 39(8): 1176-1183.
43. Zhao L, Ching LM, Kestell P, Baguley BC (2002) The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87(4): 465-470.
44. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1994) Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncology Res 6(2): 79-85.